(Q38053823)

27 August 2017

title

Prospects and challenges for the development of new therapies for Ewing sarcoma (English)

1 reference

27 August 2017

Patrick J Grohar

1

1 reference

27 August 2017

Lee J Helman

series ordinal

2

1 reference

27 August 2017

publication date

18 October 2012

1 reference

Pharmacology & Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

137

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

216-224

1 reference

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group

27 August 2017

cites work

1 reference

12 December 2020

Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data.

1 reference

12 December 2020

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study

1 reference

12 December 2020

EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

1 reference

12 December 2020

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

1 reference

12 December 2020

NMR investigation of mithramycin A binding to d(ATGCAT)2: a comparative study with chromomycin A3.

1 reference

12 December 2020

Mithramycin in the treatment of metastatic Ewing's sarcoma

1 reference

12 December 2020

The Biology of Ewing sarcoma.

1 reference

12 December 2020

Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target

1 reference

12 December 2020

A molecular function map of Ewing's sarcoma

1 reference

12 December 2020

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

12 December 2020

Topoisomerase I inhibitors: camptothecins and beyond

1 reference

12 December 2020

Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo

1 reference

12 December 2020

PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma

1 reference

12 December 2020

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

1 reference

12 December 2020

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

1 reference

12 December 2020

Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.

1 reference

12 December 2020

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin

1 reference

12 December 2020

IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.

1 reference

12 December 2020

Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

1 reference

12 December 2020

Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells

1 reference

12 December 2020

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

1 reference

12 December 2020

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

1 reference

12 December 2020

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

1 reference

12 December 2020

hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II

1 reference

12 December 2020

Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein

1 reference

12 December 2020

The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts

1 reference

12 December 2020

Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines

1 reference

12 December 2020

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

1 reference

12 December 2020

Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group

1 reference

12 December 2020

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

1 reference

12 December 2020

Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.

1 reference

12 December 2020

Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study

1 reference

12 December 2020

Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group

1 reference

12 December 2020

Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells

1 reference

12 December 2020

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

1 reference

12 December 2020

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

1 reference

12 December 2020

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study

1 reference

12 December 2020

EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma

1 reference

12 December 2020

Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma

1 reference

12 December 2020

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies

1 reference

12 December 2020

The role of PARP1 in the DNA damage response and its application in tumor therapy

1 reference

12 December 2020

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group

1 reference

12 December 2020

Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma

1 reference

12 December 2020

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

12 December 2020

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group

1 reference

12 December 2020

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

1 reference

12 December 2020

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

12 December 2020

Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes.

1 reference

12 December 2020

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

12 December 2020

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

1 reference

12 December 2020

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

1 reference

12 December 2020

Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target

1 reference

12 December 2020

Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway

1 reference

12 December 2020

Solution structure of the mithramycin dimer-DNA complex

1 reference

12 December 2020

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

1 reference

12 December 2020

EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma

1 reference

12 December 2020

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas

1 reference

12 December 2020

Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma

1 reference

12 December 2020

EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.

1 reference

12 December 2020

Modeling initiation of Ewing sarcoma in human neural crest cells

1 reference

12 December 2020

EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma

1 reference

12 December 2020

Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

1 reference

12 December 2020

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

1 reference

12 December 2020

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma

1 reference

12 December 2020

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody

1 reference

12 December 2020

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma

1 reference

12 December 2020

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

1 reference

12 December 2020

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

1 reference

12 December 2020

Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA

1 reference

12 December 2020

Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.

1 reference

12 December 2020

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

12 December 2020

Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

1 reference

12 December 2020

Epigenetic changes in pediatric solid tumors: promising new targets

1 reference

12 December 2020

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

1 reference

12 December 2020

Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors

1 reference

12 December 2020

Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions

1 reference

12 December 2020

Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration

1 reference

12 December 2020

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells

1 reference

12 December 2020

Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target

1 reference

12 December 2020

A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors

1 reference

12 December 2020

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

12 December 2020

Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells

1 reference

12 December 2020

Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons

1 reference

12 December 2020

Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells.

1 reference

12 December 2020

Initial testing of topotecan by the pediatric preclinical testing program.

1 reference

12 December 2020

The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.

1 reference

12 December 2020

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

12 December 2020

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

1 reference

12 December 2020

Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.

1 reference

12 December 2020

1 reference

12 December 2020

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

1 reference

12 December 2020

Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.

1 reference

12 December 2020

Mithramycin blocks protein binding and function of the SV40 early promoter

1 reference

12 December 2020

Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor

1 reference

12 December 2020

Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells

1 reference

12 December 2020

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

1 reference

12 December 2020

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures

1 reference

12 December 2020

Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors

1 reference

12 December 2020

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition

1 reference

12 December 2020

Reducing irinotecan-associated diarrhea in children

1 reference

12 December 2020

Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice

1 reference

12 December 2020

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs

1 reference

12 December 2020

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients

1 reference

12 December 2020

Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.

1 reference

12 December 2020

10.1016/J.PHARMTHERA.2012.10.004

Identifiers

DOI

1 reference

27 August 2017

1 reference